UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation

Block & Leviton is investigating Unicycive Therapeutics for potential securities law violations related to false or misleading statements about FDA review of its OLC New Drug Application. The company received a second Complete Response Letter on June 30, 2026, citing manufacturing deficiencies, which led to a stock price decline. Investors who have suffered losses are encouraged to contact the firm.

07/13/2026, 2:05 PM • GlobeNewswire

ALHC ALERT: Block & Leviton Investigating Alignment Healthcare, Inc. For Possible Securities Fraud; Investors Should Contact Block & Leviton to Learn More

Block & Leviton is investigating Alignment Healthcare, Inc. (ALHC) for potential securities law violations following allegations that a former executive filed a whistleblower lawsuit claiming the company manipulated finances to boost stock price and executive compensation. The stock fell approximately 16.72% following the report. The firm is also investigating Jefferies Financial Group and Unicycive Therapeutics for similar violations.

07/08/2026, 5:47 PM • GlobeNewswire

Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors

Johnson Fistel is investigating Unicycive Therapeutics after the FDA issued a second Complete Response Letter on June 30, 2026, citing the same third-party manufacturing deficiencies from a prior CRL. The FDA had not yet inspected the manufacturing vendor at the time of the resubmission. The announcement led to a decline in Unicycive's stock price, prompting investigation into potential false or misleading statements.

06/30/2026, 12:51 PM • GlobeNewswire

Important Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Integer Holdings Corp. (NYSE: ITGR): Soleno Therapeutics, Inc. (NASDAQ: SLNO); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office is investigating securities fraud claims against four companies: ASP Isotopes for allegedly making false statements about uranium enrichment technology; Integer Holdings for overstating competitive position and concealing sales deterioration; Soleno Therapeutics for misrepresenting safety profile of drug candidate DCCR/VYKAT XR; and Unicycive Therapeutics for overstating FDA manufacturing compliance readiness. Shareholders who purchased shares during specified periods may be eligible to seek corporate reforms and compensation.

03/18/2026, 9:17 AM • GlobeNewswire

Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office is investigating potential securities fraud and fiduciary duty breaches for several publicly traded companies, alleging misleading statements and incomplete disclosures that potentially harmed shareholders.

12/02/2025, 12:39 PM • GlobeNewswire

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Quantum, Unicycive, Fly-E, and Lantheus on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Law firm investigating potential securities misconduct for four companies, alleging false statements, misleading financial reporting, and concealment of material facts that impacted stock prices.

11/13/2025, 5:40 PM • GlobeNewswire

The Gross Law Firm Reminds Unicycive Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 14, 2025 – UNCY

The Gross Law Firm has issued a notice to Unicycive Therapeutics shareholders about a pending class action lawsuit alleging false statements regarding FDA manufacturing compliance and drug application regulatory prospects.

10/13/2025, 4:00 PM • GlobeNewswire

ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important October 14 Deadline in Securities Fraud Lawsuit – UNCY

Rosen Law Firm alerts Unicycive Therapeutics investors about a securities fraud lawsuit, claiming the company made false statements about FDA manufacturing compliance and drug application prospects.

10/12/2025, 2:17 PM • GlobeNewswire

UNCY INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

Faruqi & Faruqi is investigating potential securities claims against Unicycive Therapeutics after the company received a Complete Response Letter from the FDA due to manufacturing compliance issues, causing significant stock price decline.

10/12/2025, 8:52 AM • GlobeNewswire

Holzer & Holzer, LLC Reminds Investors of Upcoming Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Unicycive Therapeutics (UNCY) and KinderCare Learning Companies, Inc. (KLC)

Law firm Holzer & Holzer, LLC is alerting investors about upcoming lead plaintiff deadlines in shareholder class action lawsuits against Unicycive Therapeutics and KinderCare Learning Companies, alleging false statements and material fact omissions.

10/10/2025, 4:00 PM • GlobeNewswire

UNICYCIVE REMINDER: Bragar Eagel & Squire, P.C. Urges Investor to Contact the Firm Before the October 14th Deadline

A class action lawsuit has been filed against Unicycive Therapeutics regarding alleged misleading statements about FDA manufacturing compliance for its New Drug Application for oxylanthanum carbonate, resulting in significant stock price drops.

10/10/2025, 1:57 PM • GlobeNewswire

ROSEN, REGARDED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important October 14 Deadline in Securities Fraud Lawsuit – UNCY

Rosen Law Firm alerts Unicycive Therapeutics investors about a securities fraud lawsuit, claiming the company made false statements about FDA manufacturing compliance and drug application prospects.

10/09/2025, 11:26 PM • GlobeNewswire

UNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against Unicycive Therapeutics alleging false and misleading statements about FDA manufacturing compliance and regulatory prospects during the period of March 29, 2024 to June 27, 2025.

10/09/2025, 12:00 PM • GlobeNewswire

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Fraud Lawsuit – UNCY

Rosen Law Firm is notifying Unicycive Therapeutics investors about a securities fraud class action lawsuit alleging false statements regarding FDA manufacturing compliance and drug application regulatory prospects.

10/06/2025, 7:00 PM • GlobeNewswire

UNCY INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive

Faruqi & Faruqi is investigating potential securities claims against Unicycive Therapeutics after the company received a Complete Response Letter from the FDA due to manufacturing compliance issues, causing significant stock price decline.

10/05/2025, 11:43 PM • GlobeNewswire